The clinical success of anti–PD-1/PD-L1 therapy is mainly due to the reactivation of tumor antigen-specific T cells, which are inactivated by the binding of PD-1 on T cells to its ligand PD-L1 on tumor cells [17,18]. Here, CD274 is linked to neoplasm.